Alzheimer's Disease

IGC Pharma has announced that dosing has commenced at one of its sites participating in a phase 2b clinical trial of a combination therapy for agitation in dementia related to Alzheimer’s disease.

A Boston-area biotech company has received $24 million in Series A funding to develop neurorestorative and remyelinating therapies for a broad range of neurological conditions.

Sleep fragmentation, rather than sleep duration or self-reported sleep quality, in early midlife was associated with worse executive function, fluency and cognition more than a decade later, according to research in Neurology.

In a cohort of older adults, those with the highest percentage of high-density lipoprotein cholesterol had a 27% higher risk of incident dementia, with the risk higher for those aged 75 years and older, according to a study.

A neurotech company has announced an agreement with a radiopharmaceutical firm for the rights to manufacture an investigational imaging biomarker used in PET scans to assess the status of amyloid plaque in the brain.

Healio Neurology looks back at the most-viewed stories throughout the year. Highlights include the FDA’s approval of Leqembi to treat Alzheimer’s disease and the regulatory body’s clearing of a blood test for concussions.

Bristol Myers Squibb and Karuna Therapeutics Inc. announced a definitive merger agreement that includes Karuna’s lead asset, a muscarinic receptor agonist to treat schizophrenia and Alzheimer’s disease psychosis.

Meaningful progress is being made in the development of gene therapies for rare neurological diseases caused by single gene mutations.

The FDA has cleared for marketing “the world’s first” cloud-based software for clinical analysis of neuromelanin-sensitive MRI scans, according to a press release from the manufacturer.

AbbVie Inc. has acquired Cerevel Therapeutics and its pipeline of clinical stage and preclinical neuroscience candidates in development to address conditions such as Parkinson’s disease, schizophrenia and mood disorders.